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To the Editor: We read with great interest the article by
Ashby et al.1 reporting that plasma hepcidin-25 levels—
measured by a novel radioimmunoassay—are elevated in
renal disease, and that this mechanism is positively correlated
with ferritin level but inversely correlated with glomerular
filtration rate.
Ashby et al. reported, unlike another recent study,2 that
hepcidin-25 levels did not decrease at all in six patients
during a single ‘standard’ hemodialysis (HD) session. This
finding is surprising given the molecular weight of hepcidin-
25 (2789 Da2), thus predicting substantial clearance at least
by high-flux HD membranes.3 In order to understand these
discrepancies, could the authors detail what is currently a
‘standard’ HD procedure in London?
In addition, by multivariate regression analysis, cholester-
ol level was found to be inversely correlated (P¼ 0.018) with
plasma hepcidin level among 94 hemodialyzed patients,
which is a finding that was not discussed by the authors.
Fluvastatin 80 mg per day was recently shown to decrease not
only total cholesterol and high-sensitive C-reactive protein
levels, but also prohepcidin serum levels in dyslipidemic
dialyzed patients.4 We therefore wonder whether statin use
might account for the negative independent relation-
ship between hepcidin and cholesterol levels in the study of
Ashby et al.
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As Morelle et al.1 point out, one might expect to see a
reduction in plasma hepcidin levels post dialysis—on size
considerations alone, perhaps a 20–30% reduction would be
anticipated, but in the six patients studied in our report,2
no reduction was observed. These patients were dialyzed
for 4 h using 2.1 m2 low-flux acetate membranes with a
minimum ultrafiltrate volume of 2 l, delivering a dialysis
dose (spKt/V) of over 1.5 in all patients.
Although this may simply reflect a type 2 error—with a
sample of six patients a small reduction might not be
detected (95% confidence interval¼ 80–120% for the
post–pre dialysis hepcidin ratio)—other explanations
should not be overlooked. For example, hepcidin might
be secreted into the circulation in appreciable quantities
during dialysis, or, alternatively, clearance may be less than
expected, because of aggregation or binding to larger
plasma proteins such as alpha-2-macroglobulin.3
The inverse relationship between cholesterol and hepcidin
was not explained by statin use, which was not predictive of
hepcidin level in bivariate or multivariate analysis. Any
cholesterol association is perhaps more likely to result from
the inverse correlation between cholesterol and interleukin-
6, although it should be emphasized that these associations,
based on multiple comparisons, are relatively weak.
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